Treatment of Cushing Syndrome from Exogenous Steroid Use
The primary treatment for exogenous Cushing syndrome is to discontinue or gradually taper the causative glucocorticoid while monitoring for glucocorticoid-induced adrenal insufficiency, which should be assumed to be present in all patients with signs of exogenous Cushing syndrome. 1
Immediate Management Approach
Step 1: Recognize the Underlying Problem
Patients presenting with features of exogenous Cushing syndrome from glucocorticoid use should be assumed to have glucocorticoid-induced adrenal insufficiency 1. This is critical because abrupt cessation can precipitate adrenal crisis.
Step 2: Determine if Tapering is Appropriate
Do NOT attempt to taper if:
- The underlying disease requiring glucocorticoids is not controlled
- Glucocorticoids are still medically necessary 1
Proceed with tapering only when:
- The underlying condition is controlled
- Glucocorticoids are no longer required for the primary indication
Step 3: Initial Tapering Strategy (Supraphysiologic Doses)
For patients on supraphysiologic doses (e.g., >7.5 mg prednisone daily):
- Taper relatively rapidly down to physiologic dose equivalent (4-6 mg prednisone daily or 15-25 mg hydrocortisone daily) 1
- Do NOT test for adrenal insufficiency while on supraphysiologic doses—HPA axis suppression is expected 1
- Switch long-acting glucocorticoids (dexamethasone, betamethasone) to shorter-acting forms (hydrocortisone or prednisone) when no longer needed 1
Common Pitfall: Glucocorticoid withdrawal syndrome will occur in up to 50% of patients during tapering 1. Symptoms include myalgias, weakness, fatigue, sleep disturbances, and mood changes—these overlap with adrenal insufficiency but occur at doses too high to cause true adrenal insufficiency. If severe, temporarily increase the dose to the most recently tolerated level and extend the taper duration 1.
Step 4: Final Tapering from Physiologic Doses
Once at physiologic dose equivalent (4-6 mg prednisone or 15-25 mg hydrocortisone daily), choose one of two approaches 1:
Option A: Clinical Monitoring Approach
- Continue gradual tapering while monitoring for signs/symptoms of adrenal insufficiency
- Watch for: severe fatigue, hypotension, nausea, vomiting, hypoglycemia
- If symptoms develop, restart glucocorticoids and do not discontinue until HPA axis recovery is documented
Option B: Biochemical Confirmation Approach (Preferred when feasible)
Measure morning serum cortisol (8:00-9:00 AM, 24 hours after last glucocorticoid dose) 1:
Interpretation:
- >300 nmol/L (10 μg/dL): HPA axis recovered—stop glucocorticoids safely
- 150-300 nmol/L (5-10 μg/dL): Continue physiologic dose, retest in weeks to months
- <150 nmol/L (5 μg/dL): Continue physiologic dose, retest in several months
Do NOT routinely perform dynamic testing (ACTH stimulation test) during tapering 1
Critical Management Points
Stress Dose Coverage
All patients with current or recent glucocorticoid use who have not been biochemically cleared must receive stress dose coverage 1:
- Minor stress: Oral glucocorticoids (2-3x usual dose)
- Major stress/surgery/hemodynamic instability: Parenteral glucocorticoids (hydrocortisone 100 mg IV) plus fluid resuscitation 1
When to Refer to Endocrinology
- No HPA axis recovery after 1 year on physiologic replacement 1
- History of adrenal crisis 1
- Difficulty managing withdrawal symptoms
Special Considerations
High-risk patients for adrenal insufficiency include those using 1:
- Non-oral formulations (inhaled, topical, intra-articular)
- Multiple glucocorticoid formulations simultaneously
- High-dose inhaled/topical glucocorticoids >1 year
- Intra-articular injections within 2 months
- Concomitant CYP3A4 inhibitors
What NOT to Do
- Do NOT use fludrocortisone in glucocorticoid-induced adrenal insufficiency 1
- Do NOT taper patients on short-term therapy <3-4 weeks—just stop abruptly regardless of dose 1
- Do NOT reduce below physiologic replacement doses until HPA axis recovery is confirmed 1